Indeed, tumor microenvironment participates in resistance to molecular-targeted drugs as well as in neoplastic cells spreading: the role of HGF/c-MET axis activation in these processes has been often demonstrated and therapeutically tackled in solid tumors [11], while only a limited number of studies has instead exploited this possibility in hematological neoplasms. The gene discussed is HGF; the disease is neoplasm.